Skip to main content
Lucas G. Hill on Muck Rack

Lucas G. Hill

As seen in: Color Research & Application, Wiley, British Pharmacological Society, Daily Express, Harm Reduction Journal, Archives of Public Health, JAMA (The Journal of the American Medical Association), Psiquiatria.com, American Journal of Pharmaceutical Education, Journal of the American Pharmacists Association
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lucas G.

Contact Lucas G., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy | Archives of Public Health | Full Text

|
By Tyler J. Varisco, Hannah Fish, David Dadiomov, Lucas G. Hill, Ekere J. Essien, Matthew A. Wanat, Diane B. Ginsburg, Douglas Thornton, Joshua Bolin, Jeanne Waggener, Sahar Yazdanfard, Juhyeon Song, Whanhui Chi
| Archives of Public Health Verified
Pharmacy practice is governed by a wide array of clinical and regulatory stakeholders that often issue seemingly conflicting guidance and policy for practicing pharmacists. Clinical guidelines for the management of opioid use disorder provide a strong, clinical rationale for pharmacists to actively participate in treatment by dispensing buprenorphine and providing cognitive services, including counseling, to patients prescribed buprenorphine [1, 14, 15].
Open in Who Shared Issue with article?

Reducing the harms of xylazine: clinical approaches, research deficits, and public health context - Harm Reduction Journal

|
By Claire Zagorski, Christopher Moraff Verified, Aaron Ferguson, Mary C. Figgatt, Shoshana Aronowitz, Natalie Stahl, Lucas G. Hill, Zoe A McElligott, Nabarun Dasgupta, Rebecca A. Hosey
| Harm Reduction Journal Verified
Three primary domains of harm have emerged in relation to xylazine exposure via the unregulated drug supply—acute poisoning, prolonged sedation, and skin wounds. While there is a dearth of clinical research evaluating acute and chronic xylazine exposure in humans, collected reports from across North America reveal actionable strategies which can be employed quickly to reduce harms related to xylazine use.
Open in Who Shared Issue with article?

Medicamentos para el trastorno por uso de opioides en los programas de recuperación profesional en los Estados Unidos

|
By Lindsey J. Loera, Lucas G. Hill, Morgan L. Murchison
| Psiquiatria.com
El uso de medicamentos para el trastorno por uso de opioides (MOUD) por parte de profesionales de la salud que participan en programas de recuperación profesional (PRP) es un tema de controversia persistente. Sin embargo, las discusiones sobre este tema están limitadas por la dependencia de publicaciones obsoletas e informes anecdóticos. El propósito de este estudio fue describir las políticas actuales y los patrones de recomendación de los médicos para MOUD en los PRP.
Open in Who Shared Issue with article?
See all 15 licensed articles (19 Total)